STOCKHOLM, Sweden--(BUSINESS WIRE)--Biovitrum (STO:BVT): January – March
Net revenues for the first quarter decreased by 12 percent to SEK 352.9 M (403.3)
Net profit for the first quarter amounted to SEK 44.1 M (86.3) and earnings per share before dilution to SEK 1.0 (1.7)
Cash flow from operations amounted to SEK 48.1 M (72.8), cash and cash equivalents and short-term investments as of March 31 amounted to SEK 898.5 M (1,613.9)
